Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) Market Outlook

Thelansis’s “Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Steroid-Refractory Acute Graft-Versus-Host Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) Overview

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a life-threatening condition when the first-line treatment for acute graft-versus-host disease (aGVHD), systemic corticosteroids, does not work. aGVHD is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT), occurring in 30-50% of patients. It is caused by the donor's immune cells attacking the recipient's tissues. The incidence and severity of aGVHD are influenced by various risk factors. It tends to occur more frequently and with greater severity in cases of alloHCT from HLA-nonidentical or unrelated donors compared to HLA-matched sibling donors. Additional non-HLA risk factors associated with aGVHD encompass older patient or donor age, the utilization of a female donor for a male recipient, the use of peripheral blood as the source of stem cells, the choice of GVHD prophylaxis, and the recipient's seropositivity for cytomegalovirus. The European Society for Blood and Marrow Transplantation (EBMT) – European Leukemia Net (ELN) consensus working group has generated recommendations on treating aGvHD. In around one-third of cases, the disease is not improved after 4 weeks of treatment. Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) presents a significant challenge to healthcare providers caring for patients post-allogeneic hematopoietic cell transplantation. Extracorporeal photopheresis (ECP) and anti-thymocyte globulin (ATG) are commonly employed in treating SR-GvHD, with ECP demonstrating particular effectiveness in cases involving the skin, liver, and gut. However, there is no universally accepted standard of care for SR-aGVHD. Patients with steroid-resistant acute graft-versus-host disease (aGVHD) face a grim prognosis, with mortality rates exceeding 90%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: